ACT-500 / Xiamen Amoytop Biotech - LARVOL DELTA

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Initiation date: May 2026 ➔ Oct 2026

Trial initiation date • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • APOB

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Initiation date: Mar 2026 ➔ Oct 2026

Trial initiation date • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • APOB

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Xiamen Amoytop Biotech Co., Ltd.

New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • APOB

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Xiamen Amoytop Biotech Co., Ltd.

New P1 trial • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • APOB

Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Recruiting ➔ Completed

Trial completion • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis